×

British cancer drug developer Ellipses Pharma considers London listing

By Thomson Reuters Nov 18, 2026 | 3:18 AM

(Corrects typographical error in headline)

Nov 18 (Reuters) – British cancer drug developer Ellipses Pharma on Wednesday said ​it was exploring a London ‌listing through a deal with  special purpose acquisition company Wolfram Resources.

• Established in 2017, Ellipses Pharma’s pipeline includes trials ‌for ​drugs to treat ⁠non-small cell lung cancer ⁠and breast cancer

• The company plans to list its shares on the London bourse following a ​reverse takeover by shell company Wolfram Resources, whose terms ⁠are yet to ⁠be agreed

• The floatation will ​provide a much-needed boost to the ​UK’s market which has seen ‌an exodus from companies eyeing higher valuations in markets like the United States

• Ellipses Pharma said ⁠it is targeting completing the transaction by early 2027

• The firm also expects ⁠an equity ‌fundraise in conjunction with ⁠the deal

• Listing through ​a ‌reverse takeover process will ​enable the ⁠company to raise additional capital from public company investors, founder and chair Chris Evans said

(Reporting by Simone Lobo in Bengaluru; Editing by ​Nivedita Bhattacharjee)